0
Signin
countryflagUS

18889881171

AAPL 213.49 1.8171% MSFT 388.56 2.5847% NVDA 121.67 5.2691% GOOGL 165.49 1.6773% GOOG 167.62 1.7544% AMZN 197.95 2.094% META 607.6 2.963% AVGO 195.54 2.1844% LLY 813.48 1.4757% TSLA 249.98 3.8641% TSM 174.09 1.457% V 331.8 0.9892% JPM 232.44 3.2195% UNH 488.65 1.4807% NVO 77.15 1.6603% WMT 85.35 1.0059% LVMUY 132.18 1.865% XOM 111.9 2.9723% LVMHF 662.0 1.0687% MA 527.64 1.5024%
AAPL 213.49 1.8171% MSFT 388.56 2.5847% NVDA 121.67 5.2691% GOOGL 165.49 1.6773% GOOG 167.62 1.7544% AMZN 197.95 2.094% META 607.6 2.963% AVGO 195.54 2.1844% LLY 813.48 1.4757% TSLA 249.98 3.8641% TSM 174.09 1.457% V 331.8 0.9892% JPM 232.44 3.2195% UNH 488.65 1.4807% NVO 77.15 1.6603% WMT 85.35 1.0059% LVMUY 132.18 1.865% XOM 111.9 2.9723% LVMHF 662.0 1.0687% MA 527.64 1.5024%

Protagonist Therapeutics Inc

Healthcare US PTGX

54.78USD
-0.12(0.22%)

Last update at 2025-03-14T20:25:00Z

Day Range

53.5355.39
LowHigh

52 Week Range

13.7233.34
LowHigh

Fundamentals

  • Previous Close 54.90
  • Market Cap1752.82M
  • Volume1236872
  • P/E Ratio11.77
  • Dividend Yield-%
  • EBITDA149.64M
  • Revenue TTM314.95M
  • Revenue Per Share TTM5.31
  • Gross Profit TTM 26.58M
  • Diluted EPS TTM2.54

Analyst Recommendations

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-31-120M-100M-80M-60M-40M-20M0M20M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M100M200M300M400M500M600M700M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-40M-30M-20M-10M0M10M20M30M40M50M60M70M80M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-110M-105M-100M-95M-90M-85M-80M-75M-70M-65M-60M-55M-50M-45M-40M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -127.39300M -125.55100M -64.84500M -77.87800M -39.72300M
Minority interest - - - - -
Net income -123.41300M -122.62700M -66.15000M -77.18700M -38.92400M
Selling general administrative 31.74M 27.20M 18.64M 15.75M 13.70M
Selling and marketing expenses - - - - -
Gross profit 26.58M 27.36M 28.63M 0.23M 30.93M
Reconciled depreciation 3.37M 2.77M 2.56M 2.50M 0.53M
Ebit -134.74200M -125.84500M -64.51600M -80.52100M -42.79600M
Ebitda -131.37300M -125.55100M -63.66200M -77.70900M -42.26900M
Depreciation and amortization 3.37M 0.29M 0.85M 2.81M 0.53M
Non operating income net other 3.98M 0.29M 0.27M 2.81M 2.55M
Operating income -131.37300M -125.84500M -64.51600M -80.52100M -42.26900M
Other operating expenses 157.95M 153.20M 93.14M 80.75M 73.19M
Interest expense 3.37M 2.48M 0.60M 0.17M 0.00000M
Tax provision 0.00000M 0.00000M 1.30M -0.69100M -0.79900M
Interest income 4.06M 0.44M 0.90M 2.81M 2.55M
Net interest income 4.06M 0.44M 0.30M 2.64M 2.55M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.98000M -2.92400M 1.30M -0.69100M -0.79900M
Total revenue 26.58M 27.36M 28.63M 0.23M 30.93M
Total operating expenses 157.95M 153.20M 93.14M 80.75M 73.19M
Cost of revenue - - - - 0.00000M
Total other income expense net 3.98M 0.29M -0.32900M 2.64M 2.55M
Discontinued operations - - - - -
Net income from continuing ops -127.39300M -125.55100M -66.15000M -77.18700M -38.92400M
Net income applicable to common shares -127.39300M -125.55100M -66.15000M -77.18700M -38.92400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 357.95M 247.93M 347.69M 324.47M 154.92M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 13.96M 0.04M 0.97M 0.31M 0.74M
Total liab 21.27M 784.68M 47.67M 44.86M 74.95M
Total stockholder equity 336.68M -536.75500M -409.36200M -283.81100M -217.66100M
Deferred long term liab - - - - -
Other current liab 19.36M 25.02M 38.62M 21.23M -10.17000M
Common stock 0.00100M - - - -
Capital stock 0.00100M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -615.71000M -536.75500M -409.36200M -283.81100M -217.66100M
Other liab - - - 0.12M 23.79M
Good will - - - - -
Other assets - 0.23M 0.23M 0.45M 1.88M
Cash 186.73M 125.74M 123.67M 117.36M 33.01M
Cash and equivalents - - - - -
Total current liabilities 21.27M 31.18M 44.02M 40.24M 35.41M
Current deferred revenue 0.00300M - 1.60M 14.48M 41.53M
Net debt -185.58600M -122.08800M -117.80700M -111.39900M -15.99500M
Short term debt 1.14M 2.52M 2.20M 1.46M 1.26M
Short long term debt - - - - -
Short long term debt total 1.14M 3.66M 5.86M 5.96M 17.01M
Other stockholder equity 952.49M 0.36M 0.30M -0.02800M 0.22M
Property plant equipment - 1.56M 6.73M 1.46M 7.72M
Total current assets 355.58M 237.35M 340.74M 315.61M 145.31M
Long term investments - - 0.00000M 2.00M -
Net tangible assets - 215.61M 300.02M 279.61M 79.96M
Short term investments 154.89M 111.61M 203.24M 188.45M 100.01M
Net receivables 10.33M 0.05M 4.36M 3.51M 6.75M
Long term debt - - - - 9.79M
Inventory -10.33200M -0.09400M 8.50M 3.98M 4.79M
Accounts payable 0.77M 3.64M 1.60M 3.08M 2.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.10500M -0.35900M -0.29900M 0.03M -0.22100M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -536.75500M -409.36200M -283.81100M -217.66100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.23M 5.95M 0.23M 0.45M 0.45M
Deferred long term asset charges - - - - -
Non current assets total 2.37M 10.57M 6.96M 8.86M 9.61M
Capital lease obligations 1.14M 3.66M 5.86M 5.96M 7.22M
Long term debt total - - - - 9.79M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 92.26M -14.75900M -90.49400M -52.74300M 2.70M
Change to liabilities -11.50000M -14.26600M 7.74M -1.70100M 7.40M
Total cashflows from investing activities 91.47M -15.86000M -90.96500M -53.71000M 2.21M
Net borrowings 14.55M - 31.52M 9.77M 9.77M
Total cash from financing activities 18.84M 129.92M 247.63M 46.04M 24.11M
Change to operating activities -9.76600M 10.21M 3.28M -1.99500M 3.85M
Net income -127.39300M -125.55100M -66.15000M -77.18700M -38.92400M
Change in cash 2.08M 6.07M 84.35M -49.22700M -23.79600M
Begin period cash flow 123.89M 117.82M 33.47M 82.69M 106.49M
End period cash flow 125.97M 123.89M 117.82M 33.47M 82.69M
Total cash from operating activities -108.13700M -107.86500M -72.48400M -41.52700M -49.94700M
Issuance of capital stock 14.55M 123.83M 255.37M 34.49M 23.18M
Depreciation 3.37M 2.77M 2.56M 2.50M 0.53M
Other cashflows from investing activities - - - -52.74300M 2.70M
Dividends paid - - - - -
Change to inventory - - - - 3.85M
Change to account receivables 1.56M 0.86M -0.99000M -2.16800M -2.77100M
Sale purchase of stock 4.45M 130.11M 216.10M 36.27M 2.44M
Other cashflows from financing activities 4.29M 6.09M 2.79M 11.54M 0.93M
Change to netincome 24.20M 18.10M 8.48M 8.36M 6.92M
Capital expenditures 0.80M 1.10M 0.47M 0.97M 0.49M
Change receivables 1.56M 0.86M 4.33M -2.16800M -2.77100M
Cash flows other operating 4.51M -17.96500M -27.71400M 31.06M -23.30600M
Exchange rate changes - - - - -
Cash and cash equivalents changes 2.17M 6.20M 84.18M -49.20100M -23.61900M
Change in working capital -7.76600M -3.31400M -19.01600M 26.14M -18.01700M
Stock based compensation 24.20M 16.39M 7.90M 8.35M 6.92M
Other non cash items -0.54900M 1.83M 0.78M -0.55700M 0.21M
Free cash flow -108.93200M -108.96600M -72.95500M -42.49400M -50.43300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PTGX
Protagonist Therapeutics Inc		 -0.12 0.22% 54.78 11.77 15.02 26.26 4.68 20.59 -13.6737
NVO
Novo Nordisk A/S		 1.26 1.66% 77.15 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 76.68 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.85 0.37% 504.77 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -13.74 2.02% 666.87 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Inc

7707 Gateway Boulevard, Newark, CA, United States, 94560-1160

Key Executives

Name Title Year Born
Dr. Dinesh V. Patel Ph.D. CEO, Pres, Sec. & Director 1957
Dr. David Y. Liu Ph.D. Chief R&D Strategy Officer 1950
Dr. Suneel K. Gupta Ph.D. Chief Devel. Officer 1958
Dr. Richard S. Shames Clinical Advisor 1960
Mr. Asif Ali Exec. VP & Chief Financial Officer NA
Mr. Mohammad Masjedizadeh Exec. VP & CTO NA
Mr. Matthew M. Gosling Exec. VP & Gen. Counsel 1971
Ms. Carena Spivey Exec. Director of HR NA
Dr. Ashok Bhandari Ph.D. Sr. VP of Discovery Chemistry & Process Research 1964
Dr. Scott Eric Plevy M.D. Exec. VP and Therapeutic Head of Gastroenterology NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.